Evidence map›Paper›PMID 23222719›Full record

ArticleJournal of bacteriology2013

LcrV mutants that abolish Yersinia type III injectisome function.

Katherine Given Ligtenberg, Nathan C Miller, Anthony Mitchell, Gregory V Plano, Olaf Schneewind

Open access · bronzeAbstract read
In one paragraph

Article in Journal of bacteriology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Regulation of the Yersinia type III secretion system: traffic control.Frontiers in cellular and infection microbiology · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Katherine Given LigtenbergHoward Taylor Ricketts Laboratory, Argonne National Laboratory, Argonne, IL, USA.
Nathan C Miller
Anthony Mitchell
Gregory V Plano
Olaf Schneewind
Argonne National Laboratory · USUniversity of Chicago · USUniversity of Miami · US

Funding

Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI SHUMAN, HOWARD A · 2003 to 2013
$87.6M
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)T32HD007009 · NICHD · UNIVERSITY OF CHICAGO · PI NANCY B SCHWARTZ · 1985 to 2026
$13.0M
Yersinia Type III Transport of Yop Proteins into Immune CellsR01AI042797 · NIAID · UNIVERSITY OF CHICAGO · PI SCHNEEWIND, OLAF · 1998 to 2013
$4.3M
NIAID NIH HHS 1-U54-AI-057153NIAID NIH HHS AI42797NIAID NIH HHS R01 AI042797NIAID NIH HHS U54 AI057153NICHD NIH HHS HD009007NICHD NIH HHS T32 HD007009
6 · The paper itself

Abstract

LcrV, the type III needle cap protein of pathogenic Yersinia, has been proposed to function as a tether between YscF, the needle protein, and YopB-YopD to constitute the injectisome, a conduit for the translocation of effector proteins into host cells. Further, insertion of LcrV-capped needles from a calcium-rich environment into host cells may trigger the low-calcium signal for effector translocation. Here, we used a genetic approach to test the hypothesis that the needle cap responds to the low-calcium signal by promoting injectisome assembly. Growth restriction of Yersinia pestis in the absence of calcium (low-calcium response [LCR(+)] phenotype) was exploited to isolate dominant negative lcrV alleles with missense mutations in its amber stop codon (lcrV(*327)). The addition of at least four amino acids or the eight-residue Strep tag to the C terminus was sufficient to generate an LCR(-) phenotype, with variant LcrV capping type III needles that cannot assemble the YopD injectisome component. The C-terminal Strep tag appears buried within the cap structure, blocking effector transport even in Y. pestis yscF variants that are otherwise calcium blind, a constitutive type III secretion phenotype. Thus, LcrV(*327) mutants arrest the needle cap in a state in which it cannot respond to the low-calcium signal with either injectisome assembly or the activation of type III secretion. Insertion of the Strep tag at other positions of LcrV produced variants with wild-type LCR(+), LCR(-), or dominant negative LCR(-) phenotypes, thereby allowing us to identify discrete sites within LcrV as essential for its attributes as a secretion substrate, needle cap, and injectisome assembly factor.

Indexed as

Amino Acid SequenceAntigens, BacterialBacteriological TechniquesGene Expression Regulation, BacterialModels, MolecularMolecular Sequence DataMutagenesis, InsertionalMutationPore Forming Cytotoxic ProteinsProtein ConformationTime FactorsYersinia enterocoliticaYersinia pestisAntigens, BacterialLcrV protein, YersiniaPore Forming Cytotoxic Proteins

Identifiers

PMID23222719
PMCPMC3562105
OpenAlexW2109407177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.